Medicare

Based on a new KFF analysis, fewer than 1 in 5 (19%) nursing facilities currently meet the minimum staffing standards set out in the final requirements of the federal rule released today by the Centers for Medicare and Medicaid Services (CMS). CMS adopted staffing standards that are similar to the…

This analysis uses the most recently-available data to examine the percentage of nursing facilities that currently meet the minimum staffing requirements in the final rule.

This data note analyzes five national surveys to assess trends in retiree health coverage among people ages 65 and older. These five surveys produce somewhat different estimates of retiree health coverage, but together paint a clear picture: the share of Medicare-age adults with employer- or union-sponsored retiree health coverage has been shrinking and appears to be on the way to extinction.

The Centers for Medicare and Medicaid Services has recently taken actions to increase transparency in Medicare Advantage, however substantial data gaps remain that limit the ability of policymakers and researchers to conduct oversight and assess the program’s performance, and for Medicare beneficiaries to compare Medicare Advantage plans offered in their area.

In this column, KFF President and CEO Drew Altman examines the conservative Republican Study Committee’s sweeping proposals to remake Medicare, Medicaid and the Affordable Care Act and their potential to make waves in this year’s elections. Whether former President Trump ignores, embraces, or repudiates their ideas will be key.

A KFF analysis shows that gross total Medicare spending on Ozempic and other similar drugs has increased dramatically in recent years – even though Medicare is explicitly prohibited by law from covering the drugs for obesity. That’s because Medicare now covers the drugs, known as GLP-1s, for other medically accepted…

This policy watch analyzes the latest data on Medicare Part D spending on GLP-1 drugs, initially approved to treat diabetes but in high demand as treatments for obesity, and shows how spending on these drugs has increased substantially in recent years.

This brief examines the financial burden of health care spending among households where all members are covered by Medicare compared to non-Medicare households.

These FAQs address questions related to prescription drug importation, including the current status of importation proposals, details of Florida’s importation program recently authorized by the FDA, and concerns and challenges with this approach.